Illumina, Inc.
ILMN
株式のランク
#604
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis... Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
株価
$268.04
最終同期: 2026-10-20
時価総額
$40.47B
変化（1日）
2.05%
変化（1年）
170.86%
国
US
取引 Illumina, Inc. (ILMN)
カテゴリー
Healthcare
Illumina, Inc.（ILMN）の収益
Jun 2026 時点の収益 TTM: $4.49B
Illumina, Inc. の最新の財務報告によると、現在の収益 (TTM) は $4.49B です。2024 年には $4.37B の収益があり、これは 2023 年の $4.50B と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Illumina, Inc. の収益履歴（2000 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $4.49B | 3.48% |
| 2025 | $4.34B | -0.69% |
| 2024 | $4.37B | -2.93% |
| 2023 | $4.50B | -0.49% |
| 2022 | $4.53B | 39.73% |
| 2021 | $3.24B | -8.58% |
| 2019 | $3.54B | 6.30% |
| 2018 | $3.33B | 21.11% |
| 2017 | $2.75B | 14.74% |
| 2016 | $2.40B | 8.05% |
| 2015 | $2.22B | 19.25% |
| 2014 | $1.86B | 30.97% |
| 2013 | $1.42B | 23.74% |
| 2012 | $1.15B | 8.81% |
| 2011 | $1.06B | 16.93% |
| 2010 | $902.74M | 35.48% |
| 2009 | $666.32M | 16.24% |
| 2008 | $573.23M | 56.28% |
| 2007 | $366.80M | 98.71% |
| 2006 | $184.59M | 151.13% |
| 2005 | $73.50M | 45.31% |
| 2004 | $50.58M | 80.43% |
| 2003 | $28.04M | 179.23% |
| 2002 | $10.04M | 303.86% |
| 2001 | $2.49M | 89.90% |
| 2000 | $1.31M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $46.34B | 931.29% |
US
|
|
| $25.11B | 458.80% |
US
|
|
| $2.71B | -39.75% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 64.08% |
US
|
